Improved bioavailability of targeted Curcumin delivery efficiently regressed cardiac hypertrophy by modulating apoptotic load within cardiac microenvironment

Toxicology and Applied Pharmacology

Volumn 290, Issue , 2016, Pages 54-65

  Ray, Aramita ^a   Rana, Santanu ^a   Banerjee, Durba ^a   Mitra, Arkadeep ^a   Datta, Ritwik ^a   Naskar, Shaon ^a   Sarkar, Sagartirtha ^a  

^a UNIVERSITY OF CALCUTTA   (India)

Author keywords

Cardiac hypertrophy; Cardiomyocyte apoptosis; Cardiomyocyte targeted delivery; Curcumin; P53 ubiquitination; P53 p300 interaction

Indexed keywords

CASPASE 3; CHITOSAN NANOPARTICLE; CURCUMIN; CYTOCHROME C; E1A ASSOCIATED P300 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN P53; BAX PROTEIN, RAT; CARBOXYMETHYL-CHITOSAN; CASP3 PROTEIN, RAT; CHITOSAN; EP300 PROTEIN, RAT; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; ENCAPSULATION; ENZYME ACTIVATION; HEART FUNCTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; MALE; MICROENVIRONMENT; NEWBORN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; UBIQUITINATION; ACETYLATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMEGALY; CELL SURVIVAL; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DOWN REGULATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; WISTAR RAT;

ACETYLATION; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BIOLOGICAL AVAILABILITY; CARDIOMEGALY; CASPASE 3; CELL SURVIVAL; CHITOSAN; CURCUMIN; CYTOCHROMES C; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; E1A-ASSOCIATED P300 PROTEIN; MYOCARDIUM; MYOCYTES, CARDIAC; NANOPARTICLES; RATS; RATS, WISTAR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84948400744     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.11.011     Document Type: Article

References (46)

1. Ahuja S., Kohli S., Krishnan S., Dogra D., Sharma D., Rani V. Curcumin: a potential therapeutic polyphenol, prevents noradrenaline-induced hypertrophy in rat cardiac myocytes. J. Pharm. Pharmacol. 2011, 63:1604-1612.
2. Akhtar F., Rizvi M.M.A., Kar S.K. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol. Adv. 2012, 30:310-320.
3. Anitha A., Divya Rani V.V., Krishna R., Sreeja V., Selvamurugan N., Nair S.V., Tamura H., Jayakumar R. Synthesis, characterization, cytotoxicity and antibacterial studies of chitosan, O-carboxy methyl and N,O-carboxy methyl chitosan nanoparticles. Carbohydr. Polym. 2009, 78:672-677.
4. Anitha A., Maya S., Deepa N., Chennazhi K.P., Nair S.V., Tamura H., Jayakumar R. Efficient water soluble O-carboxy methyl chitosan nanocarrier for the delivery of curcumin to cancer cells. Carbohydr. Polym. 2011, 83:452-461.
5. Antrobus R., Borner G.H. Improved elution conditions for native co-immunoprecipitation. PLoS One 2011, 6.
6. Balasubramanyam K., Varier R.A., Altaf M., Swaminathan V., Siddappa N.B., Ranga U., Kundu T.K. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 2004, 279:51163-51171.
7. Bandekar J. Amide modes and protein conformation. Biochim. Biophys. Acta 1992, 1120:123-143.
8. Begum A.N., Jones M.R., Lim G.P., Morihara T., Kim P., Heath D.D., Rock C.L., Pruitt M.A., Yang F., Hudspeth B., Hu S., Faull K.F., Teter B., Cole G.M., Frautschy S.A. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J. Pharmacol. Exp. Ther. 2008, 326:196-208.
9. Borah J.C., Mujtaba S., Karakikes I., Zeng L., Muller M., Patel J., Moshkina N., Morohashi K., Zhang W., Gerona-Navarro G., Hajjar R.J., Zhou M.M. A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem. Biol. 2011, 18:531-541.
10. Brooks C.L., Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011, 2:456-462.
11. Chatterjee A., Mir S.A., Dutta D., Mitra A., Pathak K., Sarkar S. Analysis of p53 and NF-κB signaling in modulating the cardiomyocyte fate during hypertrophy. J. Cell. Physiol. 2011, 226:2543-2554.
12. Das B., Young D., Vasanji A., Gupta S., Sarkar S., Sen S. Influence of p53 in the transition of myotrophin-induced cardiac hypertrophy to heart failure. Cardiovasc. Res. 2010, 87:524-534.
13. DeVine T., Dai M.S. Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. Curr. Pharm. Des. 2013, 19:3248-3262.
14. Dreger H., Westphal K., Weller A., Baumann G., Stangl V., Meiners S., Stangl K. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc. Res. 2009, 83:354-361.
15. Elliott A., Ambrose E.J. Structure of synthetic polypeptides. Nature 1950, 165:921-922.
16. Fujita T., Ishikawa Y. Apoptosis in heart failure - the role of the β-adrenergic receptor-mediated signaling pathway and p53-mediated signaling pathway in the apoptosis of cardiomyocytes. Circ. J. 2011, 75:1811-1818.
17. Gu B., Zhu W.G. Surf the post-translational modification network of p53 regulation. Int. J. Biol. Sci. 2012, 8:672-684.
18. Gupta S.C., Prasad S., Kim J.H., Patchva S., Webb L.J., Priyadarsini I.K., Aggarwal B.B. Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep. 2011, 28:1937-1955.
19. Hock A.K., Vousden K.H. The role of ubiquitin modification in the regulation of p53. Biochim. Biophys. Acta 2014, 1843:137-149.
20. Hosseinzadeh L., Behravan J., Mosaffa F., Bahrami G., Bahrami A., Karimi G. Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. Food Chem. Toxicol. 2011, 49:1102-1109.
21. Jeong C.W., Yoo K.Y., Lee S.H., Jeong H.J., Lee C.S., Kim S.J. Curcumin protects against regional myocardial ischemia/reperfusion injury through activation of RISK/GSK-3β and inhibition of p38 MAPK and JNK. J. Cardiovasc. Pharmacol. Ther. 2012, 17:387-394.
22. Kapakos G., Youreva V., Srivastava A.K. Cardiovascular protection by curcumin: molecular aspects. Indian J. Biochem. Biophys. 2012, 49:306-315.
23. Katanasaka Y., Sunagawa Y., Hasegawa K., Morimoto T. Application of curcumin to heart failure therapy by targeting transcriptional pathway in cardiomyocytes. Biol. Pharm. Bull. 2013, 36:13-17.
24. Kolev T.M., Velcheva E.A., Stamboliyska B.A., Spiteller M. DFT and experimental studies of the structure and vibrational spectra of Curcumin. Int. J. Quantum Chem. 2005, 102:1069-1079.
25. Krimm S., Bandekar J. Vibrational spectroscopy and conformation of peptides, polypeptides, and proteins. Adv. Protein Chem. 1986, 38:181-364.
26. Kundu T.K., Palhan V.B., Wang Z., An W., Cole P.A., Roeder R.G. Activator-dependent transcription from chromatin in vitro involving targeted histone acetylation by p300. Mol. Cell 2000, 6:551-561.
27. Lv X., Yu X., Wang Y., Wang F., Li H., Wang Y., Lu D., Qi R., Wang H. Berberine inhibits doxorubicin-triggered cardiomyocyte apoptosis via attenuating mitochondrial dysfunction and increasing Bcl-2 expression. PLoS One 2012, 7.
28. Mir S.A., Chatterjee A., Mitra A., Pathak K., Mahata S.K., Sarkar S. Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart. J. Biol. Chem. 2012, 287:2666-2677.
29. Mitra A., Basak T., Datta K., Naskar S., Sengupta S., Sarkar S. Role of α-crystallin B as a regulatory switch in modulating cardiomyocyte apoptosis by mitochondria or endoplasmic reticulum during cardiac hypertrophy and myocardial infarction. Cell Death. Dis. 2013, 4.
30. Mitra A., Ray A., Datta R., Sengupta S., Sarkar S. Cardioprotective role of P38 MAPK during myocardial infarction via parallel activation of α-crystallin B and Nrf2. J. Cell. Physiol. 2014, 229:1272-1282.
31. Morimoto T., Sunagawa Y., Kawamura T., Takaya T., Wada H., Nagasawa A., Komeda M., Fujita M., Shimatsu A., Kita T., Hasegawa K. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest. 2008, 118:868-878.
32. Mujtaba S., Zeng L., Zhou M.M. Modulating molecular functions of p53 with small molecules. Cell Cycle 2006, 5:2575-2578.
33. Nehra S., Bhardwaj V., Kalra N., Ganju L., Bansal A., Saxena S., Saraswat D. Nanocurcumin protects cardiomyoblasts H9c2 from hypoxia-induced hypertrophy and apoptosis by improving oxidative balance. J. Physiol. Biochem. 2015, 71:239-251.
34. Ni J., Shen Y., Wang Z., Shao D.C., Liu J., Kong Y.L., Fu L.J., Zhou L., Xue H., Huang Y., Zhang W., Yu C., Lu L.M. P300-dependent STAT3 acetylation is necessary for angiotensin II-induced pro-fibrotic responses in renal tubular epithelial cells. Acta Pharmacol. Sin. 2014, 35:1157-1166.
35. Peng J.R., Qian Z.Y. Drug delivery systems for overcoming the bioavailability of curcumin: not only the nanoparticle matters. Nanomedicine 2014, 9:747-750.
36. Rana S., Datta K., Reddy T.L., Chatterjee E., Sen P., Pal-Bhadra M., Bhadra U., Pramanik A., Pramanik P., Chawla-Sarkar M., Sarkar S. A spatio-temporal cardiomyocyte targeted vector system for efficient delivery of therapeutic payloads to regress cardiac hypertrophy abating bystander effect. J. Control. Release 2015, 200:167-178.
37. Sa G., Das T. Anti cancer effects of curcumin: cycle of life and death. Cell Div. 2008, 3:14.
38. Sarkar S., Leaman D.W., Gupta S., Sil P., Young D., Morehead A., Mukherjee D., Ratliff N., Sun Y., Rayborn M., Hollyfield J., Sen S. Cardiac overexpression of myotrophin triggers myocardial hypertrophy and heart failure in transgenic mice. J. Biol. Chem. 2004, 279:20422-20434.
39. Sen N., Kumari R., Singh M.I., Das S. HDAC5, a key component in temporal regulation of p53-mediated transactivation in response to genotoxic stress. Mol. Cell 2013, 52:406-420.
40. Shankar S., Srivastava R.K. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int. J. Oncol. 2007, 30:905-918.
41. Shishodia S. Molecular mechanisms of Curcumin action: gene expression. Biofactors 2012, 39:37-55.
42. Sun C., Sze R., Zhang M. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J. Biomed. Mater. Res. A 2006, 78:550-557.
43. Sunagawa Y., Morimoto T., Wada H., Takaya T., Katanasaka Y., Kawamura T., Yanagi S., Marui A., Sakata R., Shimatsu A., Kimura T., Kakeya H., Fujita M., Hasegawa K. A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ. J. 2011, 75:2151-2159.
44. Yallapu M.M., Jaggi M., Chauhan S.C. Beta-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloids Surf. B: Biointerfaces 2010, 79:113-125.
45. Yu W., Wu J., Cai F., Xiang J., Zha W., Fan D., Guo S., Ming Z., Liu C. Curcumin alleviates diabetic cardiomyopathy in experimental diabetic rats. PLoS One 2012, 7.
46. Zuo Z.F., Zhang Q., Liu X.Z. Protective effects of Curcumin on retinal Müller cell in early diabetic rats. Int. J. Ophthalmol. 2013, 6:422-424.